Crohn's disease future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 2: | Line 2: | ||
{{Crohn's disease}} | {{Crohn's disease}} | ||
=== Ustekinumab === | |||
Recent studies have found that in patients refarctory to treatment with tumor necrosis factor (TNF) antagonists, subcutaneously administered maintenance doses of ustekinumab showed a significant benefit in terms of clinical response but not remission, and were efficacious during a period of 22 weeks.<ref>https://resident360.nejm.org/content_items/ustekinumab-for-crohn-s-disease</ref> | |||
==References== | ==References== | ||
Revision as of 03:01, 20 November 2016
|
Crohn's disease |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Crohn's disease future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Crohn's disease future or investigational therapies |
|
Crohn's disease future or investigational therapies in the news |
|
Blogs on Crohn's disease future or investigational therapies |
|
Risk calculators and risk factors for Crohn's disease future or investigational therapies |
Ustekinumab
Recent studies have found that in patients refarctory to treatment with tumor necrosis factor (TNF) antagonists, subcutaneously administered maintenance doses of ustekinumab showed a significant benefit in terms of clinical response but not remission, and were efficacious during a period of 22 weeks.[1]